Are we overtreating stage I triple-negative breast cancer in Ontario? A population-based retrospective epidemiological analysis using the ICES database-Reference-Cited by-同舟云学术

Are we overtreating stage I triple-negative breast cancer in Ontario? A population-based retrospective epidemiological analysis using the ICES database

Published:2022-09-29 Issue:12 Volume:39 Page:
ISSN:1559-131X
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Shum Kathryn^ORCID,Hussein Abdulkadir,Hamm Caroline^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12032-022-01829-2.pdf

Reference32 articles.

1. An X, Lei X, Huang R, Luo R, Li H, Xu F, et al. Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: a single-center study and a meta-analysis of the published literature. Cancer. 2020;126(Suppl 16):3837–46.

2. Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014;32(20):2142–50.

3. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, et al. Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol. 2007;25(31):4952–60.

4. Steenbruggen TG, van Werkhoven E, van Ramshorst MS, Dezentjé VO, Kok M, Linn SC, et al. Adjuvant chemotherapy in small node-negative triple-negative breast cancer. Eur J Cancer. 2020;135:66–74.

5. Colonna SV, Higgins AK, Alvarez J, Saville BR, Lawrence J, Abramson VG. Analysis of risk of recurrence by subtype in ≤ 1-cm breast tumors. Clin Breast Cancer. 2016;16(3):223–31.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is neoadjuvant treatment indicated in triple negative cT1N0 breast cancer?;Revista de Senología y Patología Mamaria;2024-10

2. A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies;eBioMedicine;2024-04